MCID: OVR027
MIFTS: 23

Ovarian Squamous Cell Carcinoma malady

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Squamous Cell Carcinoma

Aliases & Descriptions for Ovarian Squamous Cell Carcinoma:

Name: Ovarian Squamous Cell Carcinoma 12 14 69
Ovarian Squamous Cell Neoplasm 12
Ovarian Squamous Cell Tumor 69

Classifications:



External Ids:

Disease Ontology 12 DOID:5531 DOID:5532
UMLS 69 C1518739

Summaries for Ovarian Squamous Cell Carcinoma

MalaCards based summary : Ovarian Squamous Cell Carcinoma, also known as ovarian squamous cell neoplasm, is related to squamous cell carcinoma and cervicitis. An important gene associated with Ovarian Squamous Cell Carcinoma is CRP (C-Reactive Protein). The drugs Paclitaxel and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include ovary.

Related Diseases for Ovarian Squamous Cell Carcinoma

Diseases related to Ovarian Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 10.3
2 cervicitis 9.9
3 dermoid cyst 9.9
4 cystic teratoma 9.9
5 teratoma 9.9
6 fallopian tube squamous cell carcinoma 9.8 CRP LINC01191
7 vaginitis 9.7
8 papilloma 9.7
9 cervical intraepithelial neoplasia 9.7

Graphical network of the top 20 diseases related to Ovarian Squamous Cell Carcinoma:



Diseases related to Ovarian Squamous Cell Carcinoma

Symptoms & Phenotypes for Ovarian Squamous Cell Carcinoma

Drugs & Therapeutics for Ovarian Squamous Cell Carcinoma

Drugs for Ovarian Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3,Phase 1 33069-62-4 36314
2
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
3
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
4
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Doxil Approved June 1999 Phase 3 31703
7 Albumin-Bound Paclitaxel Phase 3,Phase 1
8 Liver Extracts Phase 3,Phase 2,Phase 1
9 Antimitotic Agents Phase 3,Phase 1
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
11 pancreatic polypeptide Phase 3
12 Analgesics Phase 3,Phase 1
13 Adjuvants, Anesthesia Phase 3
14 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
15 Narcotics Phase 3
16 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
17 Analgesics, Opioid Phase 3
18 Anesthetics Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
22 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
23 Antibiotics, Antitubercular Phase 3,Phase 2
24 Central Nervous System Depressants Phase 3
25 Cola Nutraceutical Phase 3,Phase 2,Phase 1
26
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
27
Indinavir Approved Phase 2 150378-17-9 5362440
28
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
29
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
30
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
31
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
32
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
33
Ifosfamide Approved Phase 2 3778-73-2 3690
34
Mechlorethamine Approved Phase 2 51-75-2 4033
35
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
36
Thiotepa Approved Phase 2 52-24-4 5453
37
Succinylcholine Approved Phase 2 306-40-1 5314
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Everolimus Approved Phase 2 159351-69-6 6442177
40
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
41
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
42
nivolumab Approved Phase 2,Phase 1 946414-94-4
43
Docetaxel Approved May 1996, Investigational Phase 1, Phase 2 114977-28-5 148124 9877265
44 Alkylating Agents Phase 2,Phase 1
45
protease inhibitors Phase 2
46 HIV Protease Inhibitors Phase 2
47 Cytochrome P-450 CYP3A Inhibitors Phase 2
48 Cytochrome P-450 Enzyme Inhibitors Phase 2
49 Anti-HIV Agents Phase 2,Phase 1
50 Anti-Infective Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 72)
id Name Status NCT ID Phase
1 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
2 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
3 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3
4 Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery Not yet recruiting NCT02997553 Phase 3
5 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
6 A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck Completed NCT01059643 Phase 2
7 Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck Completed NCT00063895 Phase 1, Phase 2
8 Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During Surgery Completed NCT00003744 Phase 2
9 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2
10 High-dose ICE With Amifostine Completed NCT00003657 Phase 2
11 Chemotherapy in Treating Patients With Solid Tumors Completed NCT00003103 Phase 1, Phase 2
12 Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer Completed NCT00002515 Phase 2
13 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
14 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
15 A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Recruiting NCT02327078 Phase 1, Phase 2
16 A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Recruiting NCT02452424 Phase 1, Phase 2
17 A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors Recruiting NCT02335918 Phase 1, Phase 2
18 Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors Recruiting NCT02644369 Phase 2
19 Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations Recruiting NCT02646319 Phase 2
20 Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE) Recruiting NCT02576431 Phase 2
21 Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors Recruiting NCT02001623 Phase 1, Phase 2
22 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies Recruiting NCT03126110 Phase 1, Phase 2
23 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2
24 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) Recruiting NCT02178722 Phase 1, Phase 2
25 Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer Recruiting NCT00492778 Phase 2
26 Cabozantinib for Advanced Urothelial Cancer Active, not recruiting NCT01688999 Phase 2
27 Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma Not yet recruiting NCT03174275 Phase 2
28 A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer Terminated NCT02042885 Phase 1, Phase 2
29 QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors Terminated NCT00819169 Phase 1, Phase 2
30 A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. Unknown status NCT02193633 Phase 1
31 Laparoscopic Sentinel Lymph Node Localization in Operable Cervix Cancer Completed NCT00205010 Phase 1
32 Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors Completed NCT00006036 Phase 1
33 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Completed NCT00031681 Phase 1
34 Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel Completed NCT00003569 Phase 1
35 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
36 Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors Completed NCT00089362 Phase 1
37 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1
38 Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function Completed NCT00002901 Phase 1
39 Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors Completed NCT00066651 Phase 1
40 Immunotoxin Therapy in Treating Patients With Advanced Cancer Completed NCT00006981 Phase 1
41 Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors Completed NCT00014456 Phase 1
42 Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer Completed NCT00004065 Phase 1
43 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer Completed NCT00045006 Phase 1
44 MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma Completed NCT00020579 Phase 1
45 Spectroscopy With Surface Coils and Decoupling Completed NCT00581815 Phase 1
46 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer Completed NCT00049296 Phase 1
47 A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas Completed NCT01588678 Phase 1
48 Gene Therapy in Treating Patients With Cancer Completed NCT00004178 Phase 1
49 RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1
50 Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Recruiting NCT01772004 Phase 1

Search NIH Clinical Center for Ovarian Squamous Cell Carcinoma

Genetic Tests for Ovarian Squamous Cell Carcinoma

Anatomical Context for Ovarian Squamous Cell Carcinoma

MalaCards organs/tissues related to Ovarian Squamous Cell Carcinoma:

39
Ovary

Publications for Ovarian Squamous Cell Carcinoma

Articles related to Ovarian Squamous Cell Carcinoma:

(show all 14)
id Title Authors Year
1
Case of pure ovarian squamous cell carcinoma resistant to combination chemotherapy with paclitaxel and carboplatin but responsive to monotherapy with weekly irinotecan. ( 25511544 )
2015
2
Pure primary ovarian squamous cell carcinoma: A case report and review of the literature. ( 25435984 )
2015
3
Clinical experience in ovarian squamous cell carcinoma arising from mature cystic teratoma: A rare entity. ( 25105100 )
2014
4
De novo Ovarian Squamous Cell Carcinoma. A Case Report and Review of Literature. ( 24426735 )
2013
5
Ovarian squamous cell carcinoma which metastasized 8 years after cervical conization for early microinvasive cervical cancer: a case report. ( 21467082 )
2011
6
Bilateral ovarian squamous cell carcinoma with an antecedent dermoid cyst in the left ovary. ( 21518128 )
2011
7
Ovarian squamous cell carcinoma arising from mature cystic teratoma. ( 21684828 )
2011
8
Metastatic ovarian squamous cell carcinoma. ( 18465040 )
2008
9
HPV induced ovarian squamous cell carcinoma: case report and review of the literature. ( 17333225 )
2007
10
A case of pure-type ovarian squamous cell carcinoma for which combination chemotherapy consisting of paclitaxel and carboplatin was not effective. ( 15790463 )
2005
11
A case of rapidly growing ovarian squamous cell carcinoma successfully controlled by weekly paclitaxel-carboplatin administration. ( 11104632 )
2000
12
Bilateral primary ovarian squamous cell carcinoma associated with human papilloma virus infection and vulvar and cervical intraepithelial neoplasia. A case report with review of the literature. ( 8651358 )
1996
13
Pure primary ovarian squamous cell carcinoma. ( 3276582 )
1988
14
Ovarian squamous cell carcinoma derived from a dermoid cyst presenting as vaginal metastasis and the implication of its steroid receptor levels--two case reports. ( 3943751 )
1986

Variations for Ovarian Squamous Cell Carcinoma

Expression for Ovarian Squamous Cell Carcinoma

Search GEO for disease gene expression data for Ovarian Squamous Cell Carcinoma.

Pathways for Ovarian Squamous Cell Carcinoma

GO Terms for Ovarian Squamous Cell Carcinoma

Sources for Ovarian Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....